Radiochemistry

ICPO ACADEMY FOR THERANOSTICS to Grant EACCME Credits after Accreditation by Union Européenne des Médecins Spécialistes (UEMS)

Retrieved on: 
Wednesday, March 20, 2024
Research, Other Health, Radiology, Philanthropy, Oncology, Continuing, Hospitals, Education, Foundation, Clinical Trials, Science, Biotechnology, Health, Pillar, Medical physics, Union, American Medical Association, ICPO, Radiochemistry, Patient, Accreditation, Nursing, News, Cancer, Quality of life, Continuing medical education, CME, Licensure, Curriculum, Safety, Multimedia, Physician

We are thrilled to announce the prestigious accreditation form the Union Européenne des Médecins Spécialistes (UEMS), an esteemed institution dedicated to enhancing medical education and professional standards across Europe.

Key Points: 
  • We are thrilled to announce the prestigious accreditation form the Union Européenne des Médecins Spécialistes (UEMS), an esteemed institution dedicated to enhancing medical education and professional standards across Europe.
  • Odile Jaume, CEO of the ICPO Foundation, commented on the news of UEMS: "The accreditation from UEMS is a significant milestone for the ICPO ACADEMY FOR THERANOSTICS.
  • The ICPO ACADEMY FOR THERANOSTICS offers a comprehensive online educational program, developed by the ICPO Foundation and powered by its global community of experts.
  • For one of these pillars, participants of the ICPO ACADEMY FOR THERANOSTICS receives 10 credits for their educational training.

Ratio Announces Expansion of Manufacturing Agreement with PharmaLogic for FAP-Targeted Radiopharmaceuticals

Retrieved on: 
Tuesday, March 12, 2024
Automation, Patient, CDMO, PET, FAP, Radiochemistry, Therapy

BOSTON and BOCA RATON, Fla., March 12, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced an expanded manufacturing agreement with PharmaLogic, a world-class contract development and manufacturing organization (CDMO) specializing in radiopharmaceutical production and distribution.

Key Points: 
  • BOSTON and BOCA RATON, Fla., March 12, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced an expanded manufacturing agreement with PharmaLogic, a world-class contract development and manufacturing organization (CDMO) specializing in radiopharmaceutical production and distribution.
  • "We are excited to partner with PharmaLogic, an industry-leading CDMO with over 15 years of experience in radiopharmaceutical manufacturing and supply chain solutions," said Dr. Matthias Friebe, Chief Technology Officer of Ratio.
  • "We are honored to collaborate with Ratio Therapeutics and support their pipeline of precision-targeted radiotherapies," said D. Scott Holbrook, Chief Strategy Officer and General Manager at PharmaLogic.
  • By leveraging our combined expertise and manufacturing capabilities, we aim to make these cutting-edge therapies readily available to patients in need."

Nusano Opens Radiochemistry Laboratory to Advance Isotope Commercialization and Customer Collaboration

Retrieved on: 
Monday, March 11, 2024
Actinium-225, Biotechnology, Drug development, Growth, Foot, Radionuclide, Risk, Radiochemistry, Physics, Health, Patient, Cancer

“Nusano is less than 12 months away from bringing critical, new radioisotope supplies to researchers, drugmakers and patients.

Key Points: 
  • “Nusano is less than 12 months away from bringing critical, new radioisotope supplies to researchers, drugmakers and patients.
  • We expect to begin producing non-carrier added lutetium-177 in Q1 2025, followed by actinium-225 in the second half of the year,” said Chris Lowe, CEO of Nusano.
  • Nusano is working to supply the fight against cancer by combining the company’s expertise in physics and radiochemistry to meet the medical isotope needs of today and enable the cancer radiotherapeutics of tomorrow.
  • Anna Goldberg, director of Radiochemistry and Production Operations for Nusano, added, “Nusano’s radiochemistry team is a world-class group of experts working at the forefront of their field.

Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics

Retrieved on: 
Monday, February 26, 2024
Acquisition, Drug development, GMP, TLX, ASX, Radiochemistry, Reserve Bank

Founded in 2005, IsoTherapeutics is a privately held, commercial-stage company, which provides radiochemistry and bioconjugation development and contract manufacturing services to many companies in the radiopharmaceutical industry, including Telix.

Key Points: 
  • Founded in 2005, IsoTherapeutics is a privately held, commercial-stage company, which provides radiochemistry and bioconjugation development and contract manufacturing services to many companies in the radiopharmaceutical industry, including Telix.
  • In line with Telix’s continued investment in the vertical integration of supply chain, manufacturing and development capabilities, the acquisition is expected to further enhance Telix’s in-house drug development capabilities.
  • A key driver for the acquisition is to enable Telix to bring select aspects of its development programs in-house, with the goal of reducing cost and time to achieve technical milestones.
  • The acquisition will also expand Telix’s U.S. manufacturing footprint with a site that includes a GMP1 clean room and production infrastructure suitable for clinical use.

ARTBIO and PharmaLogic Announce Supply Agreement for Lead-212 based Therapeutic Candidate AB001 for New York and Surrounding States

Retrieved on: 
Friday, January 12, 2024
Partnership, Radiopharmaceutical, Patient, The, Prostate cancer, Radiochemistry, Medical imaging

and BOCA RATON, Fla., Jan. 12, 2024 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic"), a leading radiopharmaceutical contract development and manufacturing organization, and ARTBIO, a clinical-stage radiopharmaceutical company developing a new class of alpha radioligand therapies (ARTs), today announce a manufacturing and supply agreement for ARTBIO's lead-212 (212Pb) based radiopharmaceutical candidate, AB001, for the treatment of prostate cancer.

Key Points: 
  • and BOCA RATON, Fla., Jan. 12, 2024 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic"), a leading radiopharmaceutical contract development and manufacturing organization, and ARTBIO, a clinical-stage radiopharmaceutical company developing a new class of alpha radioligand therapies (ARTs), today announce a manufacturing and supply agreement for ARTBIO's lead-212 (212Pb) based radiopharmaceutical candidate, AB001, for the treatment of prostate cancer.
  • Under the terms of the agreement, PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York, using ARTBIO's proprietary AlphaDirect™ 212Pb isolation technology.
  • Preliminary studies of radiopharmaceuticals labeled with 212Pb have been promising, indicating that 212Pb has the potential to address unmet clinical needs.
  • "By combining our expertise, we aim to make significant strides in the field of therapeutic radiopharmaceuticals and ultimately improve the lives of patients."

MIT Validates Serva Energy's Novel Production Method of Life-saving Actinium-225 Isotope

Retrieved on: 
Wednesday, November 1, 2023
Actinium, MIT, Nuclear medicine, Radiology, Thought, Clinical professor, Radiopharmaceutical, Isotopes of radium, MIT Nuclear Research Reactor, Targeted alpha-particle therapy, Mayo Clinic, Uranium mining, Radiochemistry, Serva

TEMPE, Ariz., Nov. 1, 2023 /PRNewswire/ -- Serva Energy 's sample measurement of the rare cancer-killing medical isotope Actinium-225 (Ac-225) has been validated by the MIT Nuclear Research Laboratory.

Key Points: 
  • TEMPE, Ariz., Nov. 1, 2023 /PRNewswire/ -- Serva Energy 's sample measurement of the rare cancer-killing medical isotope Actinium-225 (Ac-225) has been validated by the MIT Nuclear Research Laboratory.
  • It's the latest milestone in Serva's development of commercial quantities of Ac-225 needed for next-generation Targeted Alpha Therapies.
  • In June, Serva Energy announced a novel reactor-based method to produce significantly greater amounts of medical-grade Ac-225—marking the first time a commercial entity has used a conventional nuclear reactor to create the ultra-rare isotope.
  • "Plans to quickly optimize and scale up any production of this potentially critical medical isotope will be crucial in establishing a reliable supply of Ac-225."

Mariana Oncology Announces $175 Million Series B Financing

Retrieved on: 
Thursday, September 7, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, GMP, Carcinoma, RA, Actinium, Atlas Venture, Radiochemistry, Radiopharmaceutical, Patient, Peptide, Cancer, Eli Lilly and Company, Safety, Prostate cancer, Pharmaceutical industry, Medical imaging, Citadel

Mariana Oncology Inc., a biotechnology company pioneering a new era of radiopharmaceutical innovation to treat cancers with high unmet need, today announced the closing of an oversubscribed $175 million Series B financing co-led by Deep Track Capital and Forbion.

Key Points: 
  • Mariana Oncology Inc., a biotechnology company pioneering a new era of radiopharmaceutical innovation to treat cancers with high unmet need, today announced the closing of an oversubscribed $175 million Series B financing co-led by Deep Track Capital and Forbion.
  • Proceeds from the financing will support the advancement of Mariana Oncology’s novel portfolio of precision, next-generation radiopharmaceuticals including its lead candidate, MC-339, as the company transitions into a clinical-stage organization.
  • "The support of such a strong syndicate of new and existing investors is a testament to Mariana Oncology’s potential,” said Simon Read, Ph.D., Founder and Chief Executive Officer of Mariana Oncology.
  • “In just 18 months since our Series A, we’ve leveraged our deep expertise in peptide discovery and radiochemistry to advance a diversified portfolio of novel molecules.

ACU celebrates grand opening of science, research facility designed for advanced nuclear research reactor

Retrieved on: 
Thursday, September 7, 2023
Abilene Christian University, Nuclear Regulatory Commission, SERC, Dillards, Undergraduate education, Housing, University, Student, Georgia Tech, Engineering, Texas A&M University, Idaho National Laboratory, University of Texas at Austin, YouTube Next Lab and Audience Development Group, Natura & Co, Radiochemistry, Woman, Research, Multimedia, Science, U.S. News & World Report, Society of Experimental Test Pilots, Organization, ACU, NEXT, Imagination, News, Uranium mining, Nursing, Management, Gayle

"The Dillard Science and Engineering Research Center is a building unlike any other at ACU or on the campus of most universities across the nation," said Dr. Phil Schubert, ACU president, at the opening of the facility.

Key Points: 
  • "The Dillard Science and Engineering Research Center is a building unlike any other at ACU or on the campus of most universities across the nation," said Dr. Phil Schubert, ACU president, at the opening of the facility.
  • "This 28,000-square-foot facility will allow students, especially undergraduates, to contribute to world-class research and groundbreaking technology in ways not available at most other universities.
  • A public foyer highlights the research within the facility.
  • The SERC houses ACU's Nuclear Energy eXperimental Testing (NEXT) Lab, which has joined with Abilene-based Natura Resources to design, license and commission a molten salt-fueled research reactor.

CNL Announces Project to Significantly Increase Production of Rare Medical Isotope Actinium-225, a Promising New Weapon in the Fight Against Cancer

Retrieved on: 
Wednesday, July 26, 2023
Pharmacy, Canadian Nuclear Laboratories Research Facilities, ITM, Partnership, International, CNL, Life, Radionuclide, TAT, Waste management, Cancer, Actinium-225, Radiochemistry, Research, Antibody, Sylvia Fedoruk Canadian Centre for Nuclear Innovation, TCU Place, Biodegradable waste, International Conference on Nuclear Disarmament, Oslo, 2008, Engineering, Physics, Conference, Medical imaging, Uranium mining, Nursing, Chalk River, Isotope

SASKATOON, Saskatchewan, July 26, 2023 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology laboratory, is pleased to announce that it has signed an agreement with the Sylvia Fedoruk Canadian Centre for Nuclear Innovation, Inc. (Fedoruk Centre), that will significantly increase the global supply of Actinium-225, a ground-breaking new medical isotope. CNL’s President and CEO, Joe McBrearty, announced the new agreement during his opening remarks at the 11th International Conference on Isotopes (11ICI) earlier this week at TCU Place in Saskatoon, Saskatchewan.

Key Points: 
  • This partnership will significantly increase the annual global supply of Actinium-225, enabling continued research and clinical trials.
  • “CNL is thrilled to collaborate with the Fedoruk Centre on this initiative, which will dramatically increase the quantities of Actinium-225 available to the radiopharmaceutical community,” commented Mr. McBrearty.
  • CNL will then ship the materials to ITM, a leading radiopharmaceutical biotech company based in Germany, who will manage commercialization of the product.
  • CNL is now working to position itself as a world leader and international hub for targeted-alpha-therapy (TAT) and for the production of the Actinium-225 isotope.

EQS-News: Defence Therapeutics Inc.: DEFENCE SUCCESSFULLY COMPLETES THE FIRST MILESTONE OF ITS COLLABORATION AGREEMENT WITH ORANO

Retrieved on: 
Tuesday, July 18, 2023
DOTA, Trastuzumab, Radiopharmaceutical, Radiochemistry, Azide, Immunotherapy, USD, SAS, Click chemistry, Insight Partners, Orano, Collaboration, Therapy, Pharmaceutical industry, Fine chemical

Vancouver, BC, Canada, July 18, 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”), is pleased to announce that it has successfully reached the first milestone established in the Collaboration Agreement with Orano Support SAS on behalf of Orano SA (“Orano”), a world-renowned multinational company, headquartered in Chatillon, France, to develop the next generation radio-immunoconjugates using Defence’s intracellular targeting technology.

Key Points: 
  • Vancouver, BC, Canada, July 18, 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”), is pleased to announce that it has successfully reached the first milestone established in the Collaboration Agreement with Orano Support SAS on behalf of Orano SA (“Orano”), a world-renowned multinational company, headquartered in Chatillon, France, to develop the next generation radio-immunoconjugates using Defence’s intracellular targeting technology.
  • The first milestone consists of synthesising the AccuTOXTM peptide containing the DOTA chelator and the Azide moiety.
  • The DOTA chelator will be used to encapsulate the radioactive molecule, while the Azide moiety is used for antibody linking via click chemistry.
  • “We are pleased to successfully be in line with the timeline of our Orano collaboration agreement to develop the first radio-immuno-conjugates therapy based on the Auger electron emitter.